The Swiss National Bank continued to sell francs in the second quarter, following through on its “increased willingness” to intervene against a stronger currency.
Bloomberg Daybreak Europe is your essential morning viewing to stay ahead. Live from Brussels, we set the agenda for your day, catching you up with overnight markets news from the US and Asia. And we'll tell you what matters for investors in Europe, giving you insight before trading begins.
Stocks rose and bonds steadied after a bruising selloff as traders awaited a crucial US inflation reading for clues on the interest-rate outlook. The dollar headed for its best month since June.
Crude oil flows from the Middle East are returning toward pre-war levels despite continued risks to shipping, according to separate estimates from JPMorgan Chase and Goldman Sachs.
And OpenAI aims to raise at least $30 billion from investors in a new round of funding, after the artificial intelligence startup pushed back its plans for an initial public offering.
Today guests: Sabrina Khanniche, Pictet Asset Management, Senior Economist. (Source: Bloomberg)
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK, 4502.T) announced new data from three Phase 3 LATITUDE psoriasis studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis.
(RTTNews) - Roche Holding AG (RHHBY), a healthcare company, announced two regulatory developments, with the U.S. FDA accepting its New Drug Application (NDA) for Fenebrutinib in relapsing multiple sclerosis and primary progressive multiple sclerosis under Priority Review.
(RTTNews) - AbbVie (ABBV) announced positive interim results from the Phase 2 APEX Part B dose-regimen-finding Study of zumilokibart in adult patients with moderate to severe atopic dermatitis, supporting further development of the investigational therapy.
A nascent recovery in Chinese oil demand has begun to falter, as continued fighting in the Middle East and limited Iranian supply keep crude prices too high for private refiners, prompting some analysts to trim forecasts for the coming months.